GlaxoSmithKline ( GSK) is reportedly in talks to buy a large stake in generic-drug maker Aspen Pharmacare.

According to a report published Wednesday on the Financial Times' Web site, Glaxo may soon buy 10% of South Africa-based Aspen to bolster the U.K. drugmaker's sales in foreign and emerging markets.

The reported negotiations closely follow rumors that Glaxo might be eying Botox maker Allergan ( AGN) as an acquisition.

Glaxo shares were recently up 1.3% to $29.70.

If you liked this article you might like

JPMorgan Chase Chief Economist -- Greece Deal ‘Good for Stocks’

JPMorgan Chase Chief Economist -- Greece Deal ‘Good for Stocks’

Greece Deal ‘Good for Stocks,’ Markets Can Focus on Growth

Greece Deal ‘Good for Stocks,’ Markets Can Focus on Growth

Cramer: Stick with Glaxo

Cramer: Stick with Glaxo

The Deal: OncoMed IPO Goes Metastatic

The Deal: OncoMed IPO Goes Metastatic

7 Big-Pharma Stocks With Untapped Potential

7 Big-Pharma Stocks With Untapped Potential